Clarius Group LLC Takes Position in Scholar Rock Holding Co. (NASDAQ:SRRK)

Clarius Group LLC bought a new position in Scholar Rock Holding Co. (NASDAQ:SRRK) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 14,966 shares of the company’s stock, valued at approximately $281,000.

Several other hedge funds have also bought and sold shares of the business. Royal Bank of Canada lifted its stake in shares of Scholar Rock by 192.3% in the second quarter. Royal Bank of Canada now owns 3,493 shares of the company’s stock valued at $26,000 after buying an additional 2,298 shares in the last quarter. Amalgamated Bank lifted its position in Scholar Rock by 52.8% in the 3rd quarter. Amalgamated Bank now owns 4,217 shares of the company’s stock valued at $30,000 after acquiring an additional 1,458 shares in the last quarter. UBS Group AG increased its holdings in Scholar Rock by 279.0% during the 1st quarter. UBS Group AG now owns 4,328 shares of the company’s stock worth $35,000 after purchasing an additional 3,186 shares in the last quarter. Point72 Hong Kong Ltd increased its holdings in Scholar Rock by 1,388.7% during the 1st quarter. Point72 Hong Kong Ltd now owns 3,171 shares of the company’s stock worth $41,000 after purchasing an additional 2,958 shares in the last quarter. Finally, Alpha Paradigm Partners LLC purchased a new stake in shares of Scholar Rock in the third quarter worth approximately $50,000. Institutional investors and hedge funds own 91.08% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Edward H. Myles sold 4,744 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $15.74, for a total transaction of $74,670.56. Following the transaction, the chief financial officer now owns 210,976 shares of the company’s stock, valued at approximately $3,320,762.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Mo Qatanani sold 2,512 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $15.74, for a total value of $39,538.88. Following the completion of the transaction, the insider now directly owns 147,019 shares of the company’s stock, valued at approximately $2,314,079.06. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Edward H. Myles sold 4,744 shares of Scholar Rock stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $15.74, for a total transaction of $74,670.56. Following the completion of the transaction, the chief financial officer now owns 210,976 shares of the company’s stock, valued at $3,320,762.24. The disclosure for this sale can be found here. Insiders sold 33,844 shares of company stock valued at $534,887 over the last ninety days. 26.20% of the stock is currently owned by insiders.

Scholar Rock Stock Performance

NASDAQ SRRK opened at $13.45 on Monday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 8.80 and a current ratio of 8.80. Scholar Rock Holding Co. has a 52-week low of $5.56 and a 52-week high of $21.17. The company has a 50-day simple moving average of $15.63 and a 200 day simple moving average of $14.11.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings results on Tuesday, March 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.01). Analysts forecast that Scholar Rock Holding Co. will post -2.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on SRRK shares. Piper Sandler reaffirmed an “overweight” rating and set a $28.00 target price on shares of Scholar Rock in a research report on Tuesday, March 26th. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Scholar Rock in a research note on Tuesday, March 19th. Raymond James began coverage on shares of Scholar Rock in a research report on Thursday, March 28th. They set a “strong-buy” rating and a $30.00 price target on the stock. Wedbush reaffirmed an “outperform” rating and issued a $23.00 price objective on shares of Scholar Rock in a research report on Tuesday, January 23rd. Finally, Truist Financial reiterated a “buy” rating and issued a $20.00 price objective on shares of Scholar Rock in a research note on Wednesday, April 3rd. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $25.17.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.